Agios Pharmaceuticals IncNASDAQ:AGIO
- LAST PRICE42.6500
- TODAY'S CHANGE (%)0.6300 (1.4993%)
- Bid / Lots40.7700/ 1
- Ask / Lots42.9900/ 1
- Open / Previous Close42.0200 / 42.0200
- Day Range
- 52 Week Range
- Volume312,420
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AGIO |
|---|---|---|
| 09:32 ET | 4158 | 41.99 |
| 09:34 ET | 300 | 42.02 |
| 09:36 ET | 200 | 41.77 |
| 09:38 ET | 100 | 41.73 |
| 09:39 ET | 353 | 41.43 |
| 09:45 ET | 100 | 41.6 |
| 09:48 ET | 300 | 41.47 |
| 09:50 ET | 8943 | 41.57 |
| 09:52 ET | 300 | 41.57 |
| 09:54 ET | 550 | 41.76 |
| 09:56 ET | 1037 | 41.87 |
| 09:57 ET | 1160 | 41.93 |
| 09:59 ET | 392 | 41.97 |
| 10:01 ET | 791 | 41.87 |
| 10:03 ET | 200 | 41.695 |
| 10:06 ET | 100 | 41.695 |
| 10:12 ET | 115 | 41.7711 |
| 10:15 ET | 9878 | 41.72 |
| 10:17 ET | 3586 | 42.055 |
| 10:19 ET | 200 | 42.01 |
| 10:21 ET | 304 | 42.01 |
| 10:26 ET | 942 | 42.08 |
| 10:28 ET | 1400 | 42.08 |
| 10:30 ET | 300 | 42 |
| 10:32 ET | 453 | 42.05 |
| 10:35 ET | 200 | 42.165 |
| 10:44 ET | 100 | 42.2 |
| 10:46 ET | 393 | 42.14 |
| 10:50 ET | 100 | 42.24 |
| 10:51 ET | 100 | 42.18 |
| 10:53 ET | 200 | 42.26 |
| 10:55 ET | 1200 | 42.305 |
| 10:57 ET | 708 | 42.27 |
| 11:00 ET | 857 | 42.23 |
| 11:08 ET | 629 | 42.27 |
| 11:13 ET | 100 | 42.31 |
| 11:20 ET | 100 | 42.26 |
| 11:22 ET | 700 | 42.1601 |
| 11:24 ET | 6560 | 42.255 |
| 11:26 ET | 11587 | 42.49 |
| 11:27 ET | 2700 | 42.4 |
| 11:29 ET | 500 | 42.49 |
| 11:31 ET | 1295 | 42.46 |
| 11:36 ET | 200 | 42.53 |
| 11:38 ET | 248 | 42.56 |
| 11:40 ET | 100 | 42.58 |
| 11:42 ET | 100 | 42.59 |
| 11:47 ET | 100 | 42.66 |
| 11:51 ET | 200 | 42.59 |
| 11:54 ET | 300 | 42.58 |
| 11:58 ET | 200 | 42.45 |
| 12:02 ET | 500 | 42.375 |
| 12:03 ET | 305 | 42.33 |
| 12:07 ET | 100 | 42.29 |
| 12:09 ET | 332 | 42.34 |
| 12:14 ET | 100 | 42.28 |
| 12:16 ET | 200 | 42.34 |
| 12:20 ET | 100 | 42.31 |
| 12:21 ET | 100 | 42.3438 |
| 12:23 ET | 228 | 42.29 |
| 12:25 ET | 100 | 42.29 |
| 12:27 ET | 3261 | 42.43 |
| 12:30 ET | 484 | 42.58 |
| 12:32 ET | 400 | 42.5 |
| 12:34 ET | 400 | 42.55 |
| 12:36 ET | 200 | 42.62 |
| 12:39 ET | 300 | 42.65 |
| 12:41 ET | 692 | 42.65 |
| 12:45 ET | 200 | 42.645 |
| 12:48 ET | 120 | 42.66 |
| 12:50 ET | 1300 | 42.61 |
| 12:52 ET | 100 | 42.54 |
| 12:54 ET | 100 | 42.6 |
| 12:56 ET | 100 | 42.59 |
| 12:57 ET | 2291 | 42.59 |
| 12:59 ET | 200 | 42.62 |
| 01:01 ET | 200 | 42.63 |
| 01:06 ET | 200 | 42.63 |
| 01:08 ET | 100 | 42.69 |
| 01:12 ET | 100 | 42.59 |
| 01:14 ET | 100 | 42.65 |
| 01:15 ET | 221 | 42.645 |
| 01:17 ET | 1690 | 42.63 |
| 01:19 ET | 100 | 42.635 |
| 01:21 ET | 100 | 42.56 |
| 01:24 ET | 141 | 42.62 |
| 01:26 ET | 100 | 42.625 |
| 01:28 ET | 831 | 42.705 |
| 01:30 ET | 100 | 42.705 |
| 01:32 ET | 100 | 42.72 |
| 01:33 ET | 200 | 42.72 |
| 01:37 ET | 487 | 42.67 |
| 01:39 ET | 200 | 42.71 |
| 01:44 ET | 100 | 42.68 |
| 01:50 ET | 100 | 42.745 |
| 01:53 ET | 352 | 42.69 |
| 01:55 ET | 700 | 42.77 |
| 01:57 ET | 323 | 42.75 |
| 02:00 ET | 100 | 42.72 |
| 02:02 ET | 400 | 42.74 |
| 02:04 ET | 200 | 42.69 |
| 02:09 ET | 200 | 42.715 |
| 02:13 ET | 100 | 42.77 |
| 02:15 ET | 200 | 42.75 |
| 02:20 ET | 100 | 42.7 |
| 02:22 ET | 100 | 42.76 |
| 02:26 ET | 100 | 42.68 |
| 02:27 ET | 1048 | 42.73 |
| 02:31 ET | 200 | 42.73 |
| 02:33 ET | 200 | 42.785 |
| 02:36 ET | 153 | 42.73 |
| 02:38 ET | 793 | 42.63 |
| 02:42 ET | 100 | 42.63 |
| 02:45 ET | 236 | 42.64 |
| 02:51 ET | 100 | 42.59 |
| 02:54 ET | 213 | 42.6171 |
| 02:58 ET | 630 | 42.56 |
| 03:00 ET | 500 | 42.46 |
| 03:02 ET | 100 | 42.47 |
| 03:03 ET | 1947 | 42.63 |
| 03:07 ET | 100 | 42.59 |
| 03:09 ET | 1019 | 42.73 |
| 03:14 ET | 300 | 42.77 |
| 03:16 ET | 100 | 42.795 |
| 03:18 ET | 100 | 42.78 |
| 03:21 ET | 259 | 42.785 |
| 03:23 ET | 726 | 42.8 |
| 03:25 ET | 305 | 42.855 |
| 03:27 ET | 1533 | 42.72 |
| 03:30 ET | 1406 | 42.72 |
| 03:32 ET | 100 | 42.76 |
| 03:34 ET | 400 | 42.79 |
| 03:36 ET | 3113 | 42.705 |
| 03:38 ET | 419 | 42.73 |
| 03:39 ET | 3967 | 42.48 |
| 03:41 ET | 4001 | 42.755 |
| 03:43 ET | 400 | 42.755 |
| 03:45 ET | 428 | 42.75 |
| 03:48 ET | 400 | 42.79 |
| 03:50 ET | 1543 | 42.75 |
| 03:52 ET | 2889 | 42.79 |
| 03:54 ET | 2172 | 42.86 |
| 03:56 ET | 4847 | 42.71 |
| 03:57 ET | 4789 | 42.71 |
| 03:59 ET | 12277 | 42.65 |
Jun 15, 2024
Agios Presents Positive Results from Phase 3 -2-, from 8:45AM ET on Saturday Jun 15, 2024 by Dow Jones
8:45AM ET on Saturday Jun 15, 2024 by Dow Jones
Jun 13, 2024
DJ Agios Pharmaceuticals Price Target Announced at $46.00/Share by JP Morgan, from 5:17PM ET on Thursday Jun 13, 2024 by Dow Jones
5:17PM ET on Thursday Jun 13, 2024 by Dow Jones
Jun 6, 2024
Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET, from 9:00AM ET on Thursday Jun 06, 2024 by Dow Jones
9:00AM ET on Thursday Jun 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Agios Pharmaceuticals Inc | 2.4B | -6.8x | --- |
Celldex Therapeutics Inc | 2.3B | -12.5x | --- |
IDEAYA Biosciences Inc | 2.6B | -17.1x | --- |
Intellia Therapeutics Inc | 2.2B | -4.2x | --- |
Apogee Therapeutics Inc | 2.2B | -18.6x | --- |
Geron Corp | 2.7B | -13.1x | --- |
Company Information
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Contact Information
- Headquarters
- 88 Sidney StreetCAMBRIDGE, MA, United States 02139
- Phone
- 617-649-8600
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Jacqualyn Fouse
- Chief Executive Officer, Director
- Brian Goff
- Chief Financial Officer
- Cecilia Jones
- Chief Legal Officer
- James Burns
- Chief Medical Officer, Head - Research and Development
- Sarah Gheuens
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.4B |
|---|---|
Revenue (TTM) | $29.4M |
Shares Outstanding | 56.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.78 |
EPS | $-6.31 |
Book Value | $14.50 |
P/E Ratio | -6.8x |
Price/Sales (TTM) | 82.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,336.42% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
